
Congenica is a digital health company specializing in software and solutions for large-scale genomic data analysis and interpretation to drive Precision Medicine. Their platform automates genomic data analysis, diagnosis, and treatment solutions for healthcare providers and patients globally, reducing healthcare system burdens. They offer a CE-IVD approved clinical decision support platform covering inherited diseases, somatic cancer, pharma insights, and pathogen surveillance. Congenica is the exclusive Clinical Decision Support Partner for the NHS Genomic Medicine Service and supports international labs, academic medical centers, hospitals, and biopharmaceutical companies. Their technology integrates AI, machine learning, and automation to streamline workflows and accelerate clinical decision-making, with flexible deployment options including SaaS and on-premise.

Congenica is a digital health company specializing in software and solutions for large-scale genomic data analysis and interpretation to drive Precision Medicine. Their platform automates genomic data analysis, diagnosis, and treatment solutions for healthcare providers and patients globally, reducing healthcare system burdens. They offer a CE-IVD approved clinical decision support platform covering inherited diseases, somatic cancer, pharma insights, and pathogen surveillance. Congenica is the exclusive Clinical Decision Support Partner for the NHS Genomic Medicine Service and supports international labs, academic medical centers, hospitals, and biopharmaceutical companies. Their technology integrates AI, machine learning, and automation to streamline workflows and accelerate clinical decision-making, with flexible deployment options including SaaS and on-premise.
Sector: Clinical genomics software / digital health
Flagship product: Sapientia clinical decision-support platform (CE-marked)
Key partnership: Exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service
Latest known funding: Series C (Mar 4, 2021), $50M cited for Series C
Employee count (snapshot): 48
Clinical interpretation of genomic data at scale for diagnosis and treatment decision support
Digital health / Genomics / Biotechnology
50000000
Series C reported as US$50M / £39M; round included new and existing investors.
A Series A / seed round in April 2015 is reported but amount details in evidence are approximate (~£2.2M) and not provided as a confirmed figure here.
“Backed by a mix of UK life-science and strategic international investors including Tencent, Legal & General, Cambridge Innovation Capital, Amadeus Capital Partners, Parkwalk Advisors, Xeraya (Xereya) Capital, Puhua Capital, IDO Investments and others”